DURECT Corporation Presenting at the Lazard 1st Annual Life Sciences Conference

Download PDF:

CUPERTINO, Calif., Nov 22, 2004 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation
(Nasdaq: DRRX) announced today that it will present at the Lazard First Annual
Life Sciences Conference. The conference is being held at Mandarin Oriental
Hotel in New York, New York. Dr. Felix Theeuwes, Chairman and Chief Scientific
Officer, will be presenting at the conference on Wednesday, December 1st, 2004
at 11:00 a.m. EST.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )

A live audio webcast of the corporate presentation will be available by
accessing DURECT’s homepage at http://www.www.durect.com and clicking “Investor

    Pain Panel: The Market Outlook

Dr. Theeuwes, will also participate in a panel discussion on chronic pain,
where he will be delivering a presentation on the role of drug delivery in
transforming the specialty pain market at the Lazard Life Sciences Conference,
moderated by Megan Kate Murphy, Specialty Pharmaceuticals Analyst for Lazard.
Also participating in the pain panel is Dr. Cynthia McCormick, former Director
of FDA’s Division of Anesthetic, Critical Care and Addiction Drug Products,
and Dr. David Lee, EVP, Research & Development and Chief Scientific Officer
for Endo Pharmaceuticals. The panel discussion will be made on Wednesday,
December 1st, 2004 at 1:00 p.m. EST at Mandarin Oriental Hotel in New York,
New York.

About DURECT Corporation

DURECT Corporation is a pharmaceutical company focused on the development
of pharmaceutical systems based on its proprietary drug delivery platform
technologies that treat chronic debilitating diseases and enable biotechnology
products. These platform technologies include the SABER(TM) Delivery System (a
patented and versatile depot injectable useful for protein and small molecule
delivery), the ORADUR(TM) sustained release oral gel-cap technology (an oral
sustained release technology with several potential abuse deterrent
properties), the DURIN(TM) Biodegradable Implant (drug-loaded implant system)
and the MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable
system). DURECT also partners with pharmaceutical companies to develop and
commercialize proprietary and enhanced pharmaceutical products based on its
technologies. DURECT has five disclosed on-going development programs of which
three are in collaboration with pharmaceutical partners. Additional
information about DURECT is available at www.www.durect.com.

NOTE: SABER(TM), ORADUR(TM), DURIN(TM) and MICRODUR(TM) are trademarks of
DURECT Corporation.


Schond L. Greenway, Executive Director, Investor Relations and
Strategic Planning of DURECT Corporation, 408-777-1417
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com


Scroll to Top